

Index

- absolute risk difference (ARD), 115
 Academia.edu, 27
 Academic Clinical Fellowship (ACF), 1–2
 Academic Clinical Lectureships (ACL), 2
 academic trainee research, 1
 accuracy in epidemiological research, 131–132t, 132f, 133
 adult-onset disease, 220–221
 aetiology of epidemiological research, 122–123, 130–131
 Age-Period-Cohort models, 140
 age-standardisation, 121
 agreement studies, 134
 allocation concealment, 78
 American College of Obstetricians and Gynaecologists, 205
 American Fertility Society (mAFS), 251
 American Society of Clinical Oncology (ASCO), 24, 25
 Amyotrophic Lateral Sclerosis (ALS) charity, 25
 analysis of variance (ANOVA), 115
 analytic epidemiology, 119
 animal research and alternatives
 Animals (Scientific Procedures) Act, 84, 85–86
 benign gynaecology, 247
 ethical review process, 85
 introduction, 83–85
 overview, 217–218
 public information on, 86–87
 The Three Rs, 84, 85
 Animals (Scientific Procedures) Act (1986), 84, 85–86
 Animals in Science Committee, 85
 Animals Procedures Committee, 85
 Annual Academic Meeting at the Royal College of Obstetricians and Gynaecologists, 179
 annual appraisal presentations, 199
 antenatal corticosteroids (ACS), 204
 anti-hypertensive medication, 227
 antibiotic use trials, 205–206
 antioxidant benefits, 204
 Appraisal of Guidelines Research and Evaluation (AGREE), 50
 Assisted Reproductive Technology (ART), 247
 Association of Medical Research Charities (AMRC), 237
 Atmospheric-Pressure Chemical Ionisation (APCI), 99, 100
 attributable fraction, 130
 attrition bias, 242
 audits. *See also* clinical audit for quality improvement
 defined, 53
 epidemiology and, 211–212
 fetal medicine research, 211–212
 ideal standard in, 58
 medical research papers vs., 190–191
 minimum standard in, 58
 in writing for publication, 193
 ‘Author pays’ journals, 192–193
 backing up computer data, 200
 base rate problem, 133
 basic science research, 255–256
 Bayesian trials, 74
 benchmarking in audits, 58
 benign gynaecology
 acupuncture for endometriosis, 248
 animal research, 247
 best-practice guidelines, 242–245, 244t
 bias risk assessment, 241–242
 cell-based research, 245, 246t
 clinical appraisal, 239–241
 clinical research, 237–239, 238t, 240t
 clinical trials, 238–239, 240t
 Cochrane reviews, 242
 conclusion, 252
 dysmenorrhoea, 251
 endometriosis, 247
 epigenetics research, 247
 ethical considerations, 235
 fibroids, 248–250, 249t
 genetics research, 246
 immunohistochemistry, 245, 246f
 implication for research, 248
 introduction, 235
 laboratory research, 245–247
 longitudinal studies, 238
 menorrhagia, 250–251
 meta-analysis, 242, 243f
 ovulation suppression, 248t, 248
 proteomics research, 247
 qualitative research, 238
 quality of evidence, 241f, 241
 research funding, 237
 research process, 236t, 236–237
 study design, 237f, 237
 surgical findings, 251, 252f
 systematic literature reviews, 242
 tissue-based research, 245–246
 best-practice guidelines, 242–245, 244t
 bias
 attrition bias, 242
 detection bias, 242
 epidemiological research, 126, 127t
 performance bias, 241
 reporting bias, 242
 risk assessment, 241–242
 selection bias, 241
 in statistics, 113
 bibliographic databases, 31, 33–34
 binary variables, 111
 bioinformatics, 101
 biological plausibility, 123
 biomedical research. *See* animal research and alternatives
 block randomisation, 78
 blogging by doctors, 28
 body language during presentations, 186
 Bolam test, 144
 Boyd Group, 85
 broadsheet papers, 39
 Caesarean section, 230
 Caldicott Principles, 59
 Canadian Cancer Society, 25
 Cancer Research UK, 257
 candidate genes, 90
 capillary electrophoresis, 99, 100
 career development research, 4
 case-control studies, 124f, 124–125t, 229–230
 case-crossover design, 125–126
 case-fatality rate, 137
 case-only designs, 125–126
 case reports, 193–194
 case-time-control design, 126
 categorical variables, 111
 cell-based research, 245, 246t

- censoring in epidemiological research, 135–136
- central tendency and variation, 112
- Centre for Disease Control and Prevention, 23
- cerebral palsy (CP), 206
- Certificate Holder, 86
- Certificate of Completion of Training (CCT), 3
- cervical cancer, 258
- charity funding sources, 178
- chemical ionisation (CI), 100
- CHERRIES survey, 191
- Chief Scientist Office for Scotland, 159
- Chinese herbal medicine, 248
- CHIPS trial, 227
- chorionic villus sampling (CVS), 214–215
- chromosomal abnormalities, 88
- CIOMS guideline, 146
- circulatory redistribution ('brain sparing'), 208
- CLASP trial, 72
- clinical audit for quality improvement
- audit cycle, 55–56, 56f
 - background, 53
 - benchmarking, 58
 - data analysis, 60
 - data collection, 58–59
 - data management, 59–60
 - enablers and barriers, 61
 - evidence and, 54
 - making improvements, 60–61
 - patient reported outcomes, 55
 - preparation for, 56
 - process measures, 54
 - research *vs.*, 53
 - results, 60
 - review criteria, 57t, 57t–58
 - structural measures, 54
 - summary, 61–62
 - sustaining improvements, 61
 - target level performance, 58
- clinical epidemiology, 119
- Clinical Governance Advice, 202
- clinical life table, 135
- clinical outcomes in audits, 54–55
- clinical practice, 49–50, 146–148
- clinical records in audits, 59
- clinical research
- benign gynaecology, 237–239, 238t, 240t
 - fetal medicine research, 211
 - maternal medicine research, 226–227
 - trainees, 3–4
- Clinical Research Network (CRN)
- clinical specialties, 162
 - divisions and specialties, 159–161
 - engagement of, 163
 - overview, 150, 159, 161f
 - recruitment, reporting and monitoring, 162–163
 - reproductive health and childhood specialty, 161–162
- Clinical Research Nurse Workforce, 150
- clinical research specialty lead (CRSL), 160
- Clinical Trial Authorisation (CTA), 217
- clinical trial of an investigational medicinal product (CTIMP), 190
- clinical trials. *See also* randomised controlled trials
- benign gynaecology, 238–239, 240t
 - gynaecological oncology, 256–257
 - information sources in literature searches, 33
 - outcomes, 75–77
- clinical trials that involve medicinal products (CTIMPs), 146
- Clinician Scientist Scheme funding opportunities, 3
- cluster randomized trial, 73–74
- clustered data, 114
- Cochrane Handbook for Systematic Reviews of Interventions, 242
- Cochrane Library, 36t, 36, 49, 204
- Cochrane Systematic Reviews, 31, 242, 247, 248, 250
- coding, in analysis, 68
- coding, in data management, 107
- coherence, defined, 123
- cohort studies, 123, 124t, 125t, 229–230
- Collaborations for Leadership in Applied Health Research and Care (CLAHRC), 151
- colonoscopy research case example, 65
- Committee on Publication Ethics (COPE), 195
- comparative genomic hybridisation (CGH), 214, 220
- competence in autonomous decisions, 146–147
- computer literacy, 197–198
- computer modelling system, 83
- computer skills for social media
- Academia.edu, 27
 - blogging by doctors, 28
 - closed *vs.* open platforms, 26
 - conclusion, 28
 - credible sources, 23
 - educational and professional development, 24
 - globalised healthcare resources, 23
 - Google+, 27
 - health campaign tools, 24–25
 - hype over, 20
 - internet access equality concerns, 21–22
 - limitations of, 22
- LinkedIn, 26–27
- Mendeley platform, 27–28
- minimizing risks, 22
- platform differences, 26t, 26
- potential benefits, 20
- privacy settings, 22
- professional guidelines, 22
- professionalism concerns, 20–21
- public nature of, 22
- reasons for use, 22–25, 23f
- research impact, 25
- ResearchGate, 27
- scientific research availability, 24
- scientific social media platforms, 27
- social media defined, 20, 21f
- support networks on, 23–24
- time constraint concerns, 21, 22f
- Twitter, 26
- where to start, 25–28
- computer skills in medical research
- choosing operating system, 12–13, 13f,
 - conclusion, 18–19
 - data storage, 15–16f, 16f
 - email correspondence, 18
 - hardware requirements, 13
 - image manipulation software, 18, 19f
 - introduction, 12
 - literature searches, 14f, 14–15
 - online databases, 13–14f, 14f,
 - plagiarism, 18
 - presentation software, 17–18f, 18f,
 - spreadsheet software, 16, 17
 - statistical software, 16–17, 17f,
 - voice recognition software, 18
 - word processing, 15f, 15
- concealment of allocation, 78
- conference grant, 176
- confidence intervals in statistics, 113
- Confidential Enquiry into Maternal Deaths (CEMD), 212, 230
- confidentiality ground rule, 154
- conflicts of interest, 154, 155t
- confounding in epidemiological research, 127
- confounding in statistics, 117t
- congenital diaphragmatic hernia (CDH), 215
- congenital pulmonary airway malformations (CPAM), 216
- Conquer Cancer Foundation, 24
- consent. *See also* ethics and consent in research
- form for, 147–148
 - information in, 142, 144–146,
 - in labour, 202, 203
 - seeking/receiving, 147
 - voluntariness in valid consent, 142–143

Index

- consideration ground rule, 154
 consistency of association, 123
 CONSORT Statement, 188–189, 189t, 231
 constructive criticism, 169
 continuous variables, 111, 116f, 116f–117
 copy number variants (CNV), 88
 copyright considerations, 37–38, 195
 Core Outcome Measures in Effectiveness Trial (COMET) initiative, 231, 239
 Core Outcomes in Women's health (CROWN) initiative, 239
 cost outcomes, 55
 counterfactual definition, 122
 Coursera project, 17
 Cox regression models, 135–136
 CpG dinucleotides, 91f, 91, 93
 Criminal Records Bureau (CRB), 153
 Criteria of Causation, 123
 critical appraisal of medical literature
 checklists, 46–47
 critical questions, 41, 42t, 42–43f
 defined, 39
 diagnosis, 42f, 42
 forms of bias, 40
 formulating questions, 40–41
 further help with, 46–47
 harm, 43f
 help with patients, 44–45
 importance of, 39–40
 introduction, 39
 levels of evidence, 40t, 40
 prognosis, 42f, 42
 reliability of studies on, 40
 results of, 44, 46t
 steps in, 43
 therapy, 42–43, 43f, 43f
 validity of, 44
 CRN Specialty Groups, 151–152
 cross validation, 136
 crossover trials, 73

 Daily Record of Severity of Problems (DRSP), 77
 data analysis
 audits, 60
 linkage analysis, 89–90
 medical thesis, 199
 meta-analyses, 40t, 40
 obstetrics research, 206
 overview, 108–109
 preparation, 108
 qualitative research analysis, 67–69
 randomised controlled trials, 79
 data backup, 16
 data collection
 audits, 58–59
 qualitative research, 68
 randomised controlled trials, 79
 statistics in medical research, 110
 data encryption, 16
 data management in audits, 59–60
 data management in medical research
 analysis overview, 108–109
 analysis preparation, 108
 backing up computer data, 200
 coding, 107
 conclusion, 109
 defined, 104
 electronic vs. paper data, 105
 introduction, 104
 management of, 105, 106f
 missing data, 106–107
 missing vs. unknown data, 107
 original data, 194
 presentations of, 184
 staff employment, 107–108
 storing backup data, 109
 Data Protection Act (1998), 59, 104–105
 data storage, 15–16f, 16f, 16f
 dead fetuses, 210–211
 deadlines in medical research, 10
 Declaration of Helsinki, 146
 dedication of medical thesis, 196
 delegation in time management, 10–11
 Department of Health, 55
 descriptive epidemiology, 119, 120
 desktop computers, 13
 detection bias, 242
 diagnosis in epidemiological research, 131
 Directly Allocated Costs, 175
 discrete variables, 111
 discriminatory power, 136f, 136–138, 137f, 138f
 discussion section of research paper, 194
 disease clusters, 139
 dissertation, degrees requiring, 4–5
 distribution of data, 111–112
 dizygotic twins, 89
 DNA methylation, 91f, 91, 92–93
 DNA sequencing, 88, 93, 97, 217
 Doppler observations, 212, 213
 dose/response sequence, 123
 drugs in fetal medicine research, 216–217
 dummy tables in trial data, 104
 dysmenorrhoea, 251

 ecological fallacy, 123
 economic evaluation of RCTs, 77
 effect modification in epidemiological research, 129
 Effective Care in Pregnancy and Childbirth, 203

 electron ionisation (EI), 99, 100
 electronic data collection, 105
 electrospray ionisation (ESI), 99, 100
 email correspondence, 11, 18
 EMPIRE study, 228
 EndNote, 37
 endometrial ablation, 250–251
 endometrial cancer, 258
 Endometrial Tissue Bank, 245
 endometriosis
 acupuncture for, 248
 overview, 247
 ovulation suppression, 248t, 248
 Endometriosis Health Profile-30 (EHP-30), 77, 238
 Endometriosis Phenome and Biobanking Harmonisation Project (EPHect), 246
 engagement, defined, 151
 England and Wales National Cancer Registry, 121
 enzyme-deficiency diseases, 219
 epidemiological research
 accuracy/validity in, 131–133, 131–132t, 132f
 aetiologic fractions, 130–131
 aetiology of, 122–123
 analytic epidemiology, 119
 bias in, 126, 127t
 branches of, 119–122
 capture-recapture method, 138t, 138t–139
 case-control study, 124f, 125t, 126t
 case-only designs, 125–126
 censoring and withdrawal, 135–136
 cohort study, 123, 124t, 125t
 confounding, 127
 descriptive epidemiology, 119, 120
 diagnosis in, 131
 discriminatory power, 136f, 136f–138, 137f, 138f
 disease clusters, 139
 effect modification, 129
 establishing association, 123–127, 124t, 125t, 126t
 excess fractions, 130
 exposure and, 121, 122t
 fetal medicine, 211–212
 introduction, 119
 key concepts, 119–120
 matching in, 127
 maternal medicine research, 228–229
 morbidity and, 121
 mortality and, 120–121, 121f
 other topics in, 138–140
 probability of disease, 132–133
 prognosis, 134f, 134–135f

- prognostic groups, 136–138f, 138
- register databases, 122
- repeatability, 133–134t,
- spatial correlation, 139
- statistical modelling in, 127–129
- stratification in, 127
- test performance, 132
- theoretical epidemiology, 119
- time series, 139–140
- validation, 136f, 136f–138, 137f, 138f
- epigenetics research, 91, 92f, 92f–93, 247
- Equator network, 188
- equipment grant, 176
- equivalence trials, 74
- estates costs, 175
- esteem measures, 193
- ethical review process, 85
- ethics and consent in research
- approval for research funding, 176, 189
 - consent form, 147–148
 - disposal of pregnancy remains, 209
 - exceptions to, 143–144
 - fetal medicine research, 208–209
 - governance and good clinical practice, 146–148
 - information in consent, 144–146
 - information sources, 37–38
 - introduction, 142
 - qualitative research, 69
 - RCTs, 80
 - reasons for, 142
 - valid consent, 142–143
- ethnography in qualitative research, 66–67
- ETHOS (British Library's electronic thesis database), 31
- EU Clinical Trials Regulation, 190
- EUROCAT congenital anomaly surveillance program, 212
- European Federation of Pharmaceutical Industries and Associations (EFPIA), 239
- European Society of Gynaecological Oncology (ESGO), 257
- European Society of Human Reproduction and Embryology (ESHRE), 242, 243–244
- European Working Time Directive (EWTd), 1
- evidence based medicine (EBM). *See also* qualitative research
- audit and feedback, 50–51
 - barriers to practice, 51
 - clinical practice guidelines, 49–50
 - Cochrane Library, 49
 - computerised reminders, 50
 - educational materials, 51
 - educational meetings, 50
 - evaluation of impact, 51
 - guideline dissemination and implementation, 50–51
 - gynaecological oncology, 255
 - introduction, 48
 - local opinion leaders, 51
 - outreach visits, 50
 - systematic reviews, 48–49, 49t
 - tools, 48
- ex utero* fetal tissue, 210–211
- exclusions in RCTs, 79
- experiment, defined, 123
- explanatory trials, 72–73
- exposure and epidemiological research, 121, 122t
- factorial designs, 73t, 73t, 73
- false negatives/positives in trials, 108
- feasibility, interesting, novel, ethical, relevant (FINER), 236t, 236
- fellowship grant, 176
- fetal blood sampling, 214
- fetal cardiac interventions (FCI), 216
- fetal distress in labour, 201
- fetal endoscopic tracheal occlusion (FETO), 215
- fetal ethics, 208–209
- fetal growth restriction (FGR), 211
- fetal medicine research
- clinical research, 211
 - dead fetuses, 210–211
 - drugs, 216–217
 - epidemiology and audit, 211–212
 - ethics in, 208–209
 - fetal surgery, 215–216
 - fetal tissue research, 210
 - field of, 208
 - Human Tissue Act, 209
 - human tissue disposal, 209–210
 - invasive procedures, 214–215
 - laboratory research, 217–221
 - live fetuses, 210
 - non-invasive prenatal testing, 217
 - observational research, 212–214
 - other fetally-derived tissues, 211
 - overview, 208
- fetal programming and adult-onset disease, 220–221
- fetal stem cells, 218–220
- fetal surgery, 215–216
- fetal tissue research, 210
- fetomaternal cell trafficking, 221
- fibroids, 248–250, 249t,
- FIGO Committee for the Study of Ethical Aspects of Human Reproduction and Women's Health, 235
- First-and Second-Trimester Evaluation of Risk (FASTER) trial, 211
- fluorescence in-situ hybridisation (FISH), 88, 214, 220
- focus groups, 66
- follow-up in RCTs, 79
- fractionation, 99
- free fetal DNA (ffDNA), 214, 217
- Friends and Family Test, 55
- Full Economic Cost (FEC), 175
- Fund for the Replacement of Animals in Medical Experiments (FRAME), 83
- funding medical research
- application submission, 176–177
 - beneficiaries, 174
 - dissemination, 175
 - ethics approval, 176
 - filling in forms, 177
 - grant budget justification, 174–175
 - grant proposals, 171–172
 - grant types, 176
 - introduction, 171
 - opportunities at research meetings, 180
 - patient and public involvement, 174
 - principal sources, 177–178, 178t
 - proposal background, 172–173
 - proposal summaries, 171
 - referee selection, 177
 - research governance, 176–177
 - study design, 173–174
 - technical/lay summaries, 172
 - title of research, 172
 - writing proposal for, 171–176
- funnel plot, 60
- gas chromatography (GC), 99
- gene annotation, 97
- gene therapy, 208, 218–220
- General Medical Council (GMC), 22, 210
- general search engines, 32
- generalisability in qualitative research, 69–70
- generalisability lessons, 204–205
- generic skill research, 3–4
- genetic research
- candidate genes, 90
 - chromosomal abnormalities, 88
 - clinical translation, 94
 - DNA methylation, 91f, 91, 92–93
 - DNA sequencing, 88, 93
 - epigenetics, 91, 92f, 92f–93
 - evidence for inheritance, 89
 - genetic variation, 88
 - genotyping methods, 88–89
 - identical twins studies, 92

Index

- genetic research (cont.)
 interpreting results of, 93–94
 introduction, 88
 linkage analysis, 89–90
 molecular studies, 89–91
 overview, 246
 sample sizing, 90–91
 somatic mutations, 89
- Geneva Foundation for Medical Education and Research (GFMER), 33–34, 34t,
- genome-wide association screening (GWAS), 90, 94
- genome-wide linkage screening (GWLS), 90
- genomics, 97–98. *See also* -omic research
- genotyping methods, 88–89
- gift authorship, 195
- goals setting in research, 8–9
- gonadotrophin-releasing hormone (GnRH), 247
- Good Clinical Practice, 202
- Google+, 27
- Google Hangout, 27
- Google Scholar, 13
- goserelin use, 251
- governance and good clinical practice
 competence, 146–147
 consent form, 147–148
 information giving, 147
 overview, 146–148
 research governance, 176–177
 seeking/receiving consent, 147
 voluntariness, 148
- Grades of Recommendation, Assessment, Development and Evaluation (GRADE) Working Group, 49
- Grading of Recommendations, Assessment, Development and Evaluations (GRADE), 241
- grant budget justification, 174–175
- Growth Restriction Intervention Trial (GRIT), 211
- guideline dissemination and implementation, 50–51
- Guideline for Clinical Research on New Chinese Medicine for Treatment of Pelvic Endometriosis, 248
- gynaecological oncology
 basic science research, 255–256
 cervical cancer, 258
 clinical trials, 256–257
 conclusions, 258–259
 current research focus, 257
 endometrial cancer, 258
 funding for, 257
 ovarian cancer, 257–258
- past, present, future of, 255
 support for, 257
 translational research, 256
 types of research, 255
 vulval cancer, 258
- Gynecologic Oncology Group (GOG), 257
- haematological malignancies, 94
- haemopoietic stem cells (HSC), 218
- Harnessing Online Peer Education (HOPE), 25
- Health Act (2009), 53
- Health and Social Care Act, 159, 191
- Health and Social Care Public Health Agency Research and Development for Northern Ireland, 159
- Health Research Authority (UK), 24, 147
- Health Technology Assessment (HTA), 150
- Healthcare Quality Improvement Partnership (HQIP), 53, 212
- hiding and time management, 11
- high-dimensional biology. *See* -omic research
- high-performance liquid chromatography, 99
- high-quality biobanks, 101
- Hill, Bradford, 123
- human-based research, 83
- Human Metabolome Database, 99
- Human Papilloma virus (HPV), 258
- Human Tissue Act (2004), 209, 210, 235
- Human Tissue Authority (HTA), 209
- Human Tissue Authority (HTA) Code of Practices, 210, 211
- human tissue disposal, 209–210
- hydroflotation, 251
- hypertension in pregnancy, 228
- hypothesis testing, 113
- hypothetical construct, 122
- Ice Bucket Challenge, 25
- ideal standard in audits, 58
- identical twins studies, 92
- image manipulation software, 18, 19f
- immunohistochemistry, 245, 246f
- in utero* fetal tissue, 210–211
- in utero* haemopoietic cell transplantation (IUHCT), 219
- in utero* transplantation (IUT), 219
- in vitro* research, 245, 256
- individual patient survival, 134
- industrial collaboration grant, 176
- industry funding sources, 178
- infertility trial, 77
- information giving, 147
- information in consent, 142, 144–146
- information overload, 144
- information sources in literature
 searches
 appraising sites, 32–33
 bibliographic databases, 31, 33–34
 choosing sources, 31–32
 Cochrane Library, 36t, 36
 conclusion, 38
 defining search question, 30t, 30t–31t, 31t,
 ethical and legal use of, 37–38
 evidence sources, 33
 general resources, 32
 general search engines, 32
 Geneva Foundation for Medical Education and Research, 33–34, 34t
 guidelines, 33
 introduction, 30
 limits to, 35–36
 medical specific sources, 33
 ongoing clinical trials, 33
 recording activity and results, 36–37
 standard referencing formats, 37
 statistics, 33
 subject searching, 34, 35t
 textword searching, 34–35, 35f
 TRIP database, 32, 33
 updating search, 36
- Institute of Psychiatry (IoP), 153
- intellectual freedom, 178
- International Committee of Medical Journal Editors (ICMJE), 189, 239
- International Conference on Harmonisation (ICH), 147, 236
- International Gynecologic Cancer Society (IGCS), 257
- International Society for Obstetric Medicine, 232
- international standard randomised controlled trial number (ISRCTN), 189, 239
- International Statistical Classification of Diseases (ICD9 or I0), 238t, 238
- internet access equality concerns, 21–22
- intra-partum trials, 201–203
- intrahepatic cholestasis of pregnancy, 228
- intrapartum assessment of fetal well-being, 214
- intrinsic variability, 110
- introduction section of research paper, 194
- invasive fetal therapy, 208
- invasive procedures, 214–215
- INVOLVE organization, 150–152, 153, 155
- involvement, defined, 151

- James Lind Alliance (JLA), 150, 156
jargon ground rule, 154
Journal Citation Reports, 192
- Kaplan-Meier plot, 137
Kermack-McKendrick theorem, 119
King's College Questionnaire for Urinary Incontinence, 77
Korean Health Insurance Review and Assessment Service, 238
- Laboratory Animals Science Association (LASA), 84
laboratory meeting presentations, 199
laboratory research
 animal research, 217–218
 benign gynaecology, 245–247
 fetal medicine research, 217–221
 fetal programming and adult-onset disease, 220–221
 fetal stem cells and gene therapy, 218–220
 maternal medicine research, 231
 molecular biology, 220
 trainee advice, 221–222
 trophoblast and placenta, 218
laptops, 13, 15
legal use of information sources, 37–38
levonorgestrel-releasing intrauterine system (LNG-IUD), 247
linkage analysis in genetic research, 89–90
LinkedIn, 26–27
liquid chromatography/mass spectrometry (LC/MS), 99
literature reviewing, 198
literature searches, 14f, 14–15
live fetuses, 210
local trainee collaboratives, 165
logarithm of the odds (LOD) score, 90
low incidence outcomes, 202
- MAGPIE trial, 231
malware programs, 15
Management of Asthma in School-age Children on Therapy (MASCOT), 172
Management of Myelomeningocele Study (MOMS), 215
masking in RCTs, 78
mass spectrometry (MS), 99, 100
matching in epidemiological research, 127
Maternal, Newborn and Infant Clinical Outcome Review Programme (MNI-CORP), 212
Maternal-Fetal Medicine Units (MFMU) Network, 232
maternal medicine research
 approach to, 226, 227t
 challenges to, 226
 clinical research, 226–227
 epidemiological research, 228–229
 ethics of, 232
 harmonizing reporting, 231
 laboratory research, 231
 networks in, 232
 observational research, 229–230
 qualitative research, 230–231
 randomised controlled trials, 227–228
 scale of, 226
 secondary research, 231
 undertaking research, 232
maternal transabdominal monitoring, 213
matrix assisted laser desorption ionization (MALDI), 100
MBRRACE-UK, 212
A Measurement Tool to Assess Systematic Reviews (AMSTAR), 241
Medical Protection Society (MPS), 20
Medical Research Council (MRC)
 clinical trial registry, 190
 funding from, 157, 237
 gynaecological oncology, 257
 misconduct information, 235
 open access publication, 193
medical research papers
 answering questions about, 186–187
 audit and, 190–191
 conclusions, 187
 introduction, 183
 oral presentations, 185
 preparation of, 183
 presentation of, 186
 research meeting overview, 185–186
 visual aids, 183–185
medical thesis
 backing up computer data, 200
 computer literacy, 197–198
 dedication, 196
 fine tuning of, 199
 introduction, 196
 literature reviewing, 198
 other theses *vs.*, 198
 plan for, 198
 preparation, 196–197
 prior to starting, 196
 putting it together, 200
 referencing in, 200
 results and statistical analysis, 199
 summary, 200
 university guidelines, 198
 writing of, 199
medicinal products and RCTs, 190
Medicines and Healthcare products Regulatory Authority (MHRA), 217
Medicines Licensing Act (1968), 217
Medline database, 33–34
Mendeley platform, 27–28
meningomyelocele (MMC) repair, 215
Menopause Rating Scale, 77
menorrhagia, 250–251
Mental Capacity Act (2005), 147
mesenchymal stem cells (MSC), 218, 219
meta-analyses, 40t, 40
metabolomics, 98–99. *See also* -omic research
 methods section of research paper, 194
 microarray technology, 98
 microRNA (mRNA), 93, 94, 97. *See also* -omic research
 Microsoft Excel, 16, 17
 Microsoft Word program, 15
 middle cerebral artery (MCA), 213
 minimisation concept, 78
 minimum standard in audits, 58
 missing data, 106–107
 MMedSci degree, 5
 molecular studies, 89–91, 220
 monitoring of recruitment, 162–163
 monogenic (Mendelian) disorders, 89
 monozygotic twins, 89
Montgomery v. Lanarkshire Health Board, 144
morbidity and epidemiological research, 121
mortality and epidemiological research, 120–121f, 121f
multiple-arm parallel group, 73
multiple sclerosis (MS), 25
multiplex ligation-dependent probe amplification (MLPA), 88
myomectomy in fibroid treatment, 249t, 249t–250
- Nanostructure-Initiator Mass spectrometer, 100
National Advisory Group on Clinical Audit and Enquiries, 53
National Centre for the 3Rs (NC3Rs), 85
National Clinical Audit and Patient Outcomes Programme (NCAPOP), 53
National Confidential Enquiry into Perioperative Deaths (NCEPOD), 55
National Coordinating Centre for Public Involvement (NCCP), 157
National Health Service (NHS)
 research, 159, 175, 176
National Heavy Menstrual Bleeding (HMB) Audit, 55
National Institute for Health and Care Excellence (NICE), 1, 49, 228, 241, 242, 257

Index

- National Institute for Health Research (NIHR), 1, 11, 150, 151–152, 157, 159, 160f, 162, 193, 203, 232
- National Institute for Social Care and Health Research for Wales, 159
- National Library of Medicine (NLM), 13
- National Neonatal Audit Programme, 58
- National Perinatal Epidemiology Centre (NPEC), 212
- National Perinatal Epidemiology Unit (NPEU), 212
- National Quality Innovation Productivity and Prevention (QIPP), 55
- National Reporting and Learning Service (NRLS), 55
- National Research Ethics Service (NRES), 152, 210
- National Service Frameworks, 1
- National Specialty Lead, 161
- National UK Blog Award, 28
- network devices, 13
- networking at research meetings, 180–181
- neural stem cells, 218
- neurophysiological sensitivity, 84
- NoMakeUpSelfies Campaign, 25
- non-evidence-based practice, 202
- non-invasive prenatal testing, 217
- non-medical graduate research, 5
- non-parametric statistics, 60, 113–114
- normal distribution of data, 111
- note reading during presentations, 186
- nuclear magnetic resonance spectroscopy (NMRS), 99, 100
- Null Hypothesis (H0), 113
- Nurses' Health Study, 238
- observational research, 212–214, 229–230
- obstetrics research
 - antenatal corticosteroids, 204
 - antibiotic use trials, 205–206
 - antioxidant benefits, 204
 - conclusions, 206
 - consenting in labour, 202, 203
 - example of, 201
 - generalisability lessons, 204–205
 - intra-partum trials, 201–203
 - introduction, 201
 - low incidence outcomes, 202
 - non-evidence-based practice, 202
 - secondary analysis, 206
 - systematic review, 203–204
- odds ratio (OR), 115
- omic research
 - bioinformatics, 101
 - capillary electrophoresis, 99, 100
 - clinical example of use, 102
 - conclusion, 102
 - gas chromatography, 99
 - genomics, 97–98
 - hierarchy of, 97–99
 - high-performance liquid chromatography, 99
 - high-quality biobanks, 101
 - introduction, 97
 - mass spectrometry, 99, 100
 - metabolomics, 98–99
 - microRNA, 97
 - nuclear magnetic resonance spectroscopy, 99, 100
 - overview, 99
 - protein microarrays, 100–101
 - proteomics research, 98, 247
 - reagents, 101
 - separation techniques, 99
 - systems biology, 101–102
 - transcriptomics, 98
- one-to-one interviews, 66, 67t
- online databases, 13–14, 14f
- online resources, 16–17, 17f
- open access, 192–193
- Open Office program, 15
- open source software, 12, 14, 15
- optical character recognition (OCR), 59
- optical mark readers (OMR), 59
- optimum standard in audits, 58
- ORACLE trial, 205–206
- oral presentations at research meetings, 181
- oral presentations of medical research papers, 185
- original data, 194
- osteogenesis imperfecta (OI), 219
- Out of Programme (OOP) academic trainee, 2
- Outcomes Frameworks, 55
- outreach visits, 50
- ovarian cancer, 257–258
- OVID, 37
- ovulation suppression, 248t, 248
- paper data collection, 105
- parametric statistics, 113–114
- participation, defined, 151
- password protection, 16
- Patient Advice and Liaison Service (PALS), 152, 153
- patient and public involvement (PPI)
 - conflicts of interest, 154, 155t
 - defined, 150
 - funding medical research, 174
 - ground rules, 154
 - helpful links, 155
 - identifying helpful people, 153, 161
 - introduction, 11, 150
 - INVOLVE organization, 150–152, 153, 155
 - involving public in, 152–153
 - James Lind Alliance, 150, 156
 - parameters of, 152
 - recruitment and appointment guidelines, 153–154
 - role description within, 154
 - terms of reference, 154
 - troubleshooting, 154–155, 156t
- patient confidentiality concerns, 21
- patient identifiable data, 17
- Patient Information Advisory Group, 191
- patient preference trial, 74
- patient reported outcomes (PROMS), 55
- patient satisfaction, 77
- pelvic floor dysfunction (PFD) case study, 68
- People in Research, 157
- Percutaneous shunting in Lower Urinary Tract Obstruction (PLUTO), 215, 216
- performance bias, 241
- Personal Licence/Project Licence, 85
- personally-driven time management, 166
- pharmacogenomics, 98
- Phase 0 trials, 71
- Phase I trials, 71
- Phase II trials, 71–72
- Phase III trials, 72
- Phase IV trials, 72
- PICO clinical search question, 30t, 30t–31t, 31t
- placenta laboratory research, 218
- placental growth factor (PLGF), 230
- plagiarism, 18
- plagiarism concerns, 195
- Plain English Campaign, 157
- planning for medical research, 8
- Polkinghorne Committee, 209
- Polkinghorne guidelines, 209, 210, 211
- Poly (ADP-ribose) polymerase (PARP) inhibitors, 256
- polymerase chain reaction (PCR), 89, 93, 214
- polymorphism, 88, 94
- Popper, Karl, 194
- population, intervention, control, and outcomes (PICO), 236t, 236
- portfolio and specialty support, 162
- poster presentations at research meetings, 181
- power calculations, 77–78
- power in statistics, 113–114
- Powerpoint program, 17–18
- pragmatic trials, 72–73
- predatory publishing, 193

- predictive factors in epidemiological research, 134
- preeclampsia studies, 93, 204, 230
- preferred reporting items for systematic reviews and meta-analyses (PRISMA), 191
- premature ovarian insufficiency (POI), 243
- preparation of medical thesis, 196–197
- presentation software, 17f
- preterm infant, 201
- printing/photocopying, 198
- prioritisation in medical research, 9f
- Priority Setting Partnerships (PSPs), 150
- probability of disease, 132–133
- process measures in audits, 54
- professional practice standard, 144
- professionalism concerns with social media, 20–21
- progesterone use, 251
- prognosis in epidemiological research, 134f, 134f–135f, 135f
- prognostic index, 136f, 136f–138, 137f, 138f
- programme grant, 176
- project grant, 176
- Project Licence Holder, 83, 85
- Prospective Observational Trial to Optimise Paediatric Health in Intrauterine Growth Restriction (PORTO), 211
- prospective registration, 189–190
- PROSPERO (international prospective register of systematic reviews), 31
- protein microarrays, 100–101
- proteins. *See* -omic research
- proteomics research, 98, 247
- pseudo-anonymisation, 191
- Public Involvement Impact Assessment Framework (PiiAF), 157
- publication aims, 4–6
- PubMed, 13, 189
- QR codes, 12
- qualitative research
 - analysis of, 67–69
 - benign gynaecology, 238
 - challenges, 69
 - colonoscopy case example, 65
 - conclusion, 70
 - definitions and purpose, 64–65
 - ethics in, 69
 - ethnography, 66–67
 - focus groups, 66
 - generalisability, 69–70
 - introduction, 64
 - key methods, 65–66
- maternal medicine research, 230–231
- one-to-one interviews, 66, 67t
- pelvic floor dysfunction (PFD) case study, 68
- types of questions, 65
- vaginal prolapse case example, 69
- Quality Accounts report, 53
- Quality Adjusted Life-Year (QALY), 138
- quality of life, 77, 138f, 138
- quantitative fluorescence PCR (QF-PCR), 88
- quantitative research, 107
- quasi-randomized trial, 74
- questionnaire surveys in audits, 59
- R programming language, 17
- randomised controlled trials (RCTs). *See also* clinical trials
 - additional requirements for, 190
 - adhesions after gynaecological surgery, 251
 - analytic epidemiology, 119
 - Bayesian trials, 74
 - clinical outcomes, 75–77
 - cluster randomized trial, 73–74
 - concealment of allocation, 78
 - conclusion, 80
 - crossover trials, 73
 - data analysis, 79
 - data collection, 79
 - data management, 108
 - defining outcomes, 75, 76t
 - defining study population, 75
 - economic evaluation, 77
 - effectiveness of antenatal corticosteroids, 48
 - equivalence trials, 74
 - ethics of, 80
 - evidence based medicine, 48–49
 - exclusions, 79
 - factorial designs, 73t, 73
 - follow-up, 79
 - gynaecological oncology, 256–257
 - hypothesis testing, 113
 - interventions, 75
 - intra-partum trials, 201–203
 - introduction, 71
 - invasive fetal therapy, 208
 - levels of evidence, 40
 - masking, 78
 - maternal medicine research, 227–228
 - menorrhagia in women, 250
 - multiple-arm parallel group, 73
 - myomectomy in fibroid treatment, 250
 - patient preference trial, 74
 - patient satisfaction, 77
 - performance of, 75
 - Phase 0 trials, 71
 - Phase II trials, 71–72
 - Phase III trials, 72
 - Phase IV trials, 72
 - pilot studies, 71
 - power and sample calculations, 77–78
 - pragmatic and explanatory trials, 72–73
 - presenting results, 79
 - quality of life, 77
 - quasi-randomized trial, 74
 - randomisation overview, 78
 - research governance, 80
 - statistics in medical research, 110
 - summary of, 123, 124t
 - systematic review, 49–50, 75
 - terminology, 71, 72t
 - trial designs, 73–75
 - two-arm parallel group, 73
- rapidly fatal diseases, 120
- RCOG Green-top Guidelines, 31, 57
- RCOG standards, 57
- reagents, 101
- Receiver Operating Characteristic (ROC), 132f, 132, 230
- reduction, refinement and replacement ('The Three Rs'), 84, 85
- redundant data, 104
- redundant publication, 195
- reference managers, 14, 37
- referencing in medical thesis, 200
- register databases in epidemiological research, 122
- registry-based research, 228–229
- regulatory toxicology, 83
- relative survival cure, 137
- repeatability in epidemiological research, 133t, 133t–134t, 134t
- reporting bias, 242
- reporting guidelines, 191–192
- reporting in recruitment, 162–163
- reproductive health and childbirth (RH&C), 160, 161–162
- Research Design Service (RDS), 11, 151, 157
- Research Ethics Committee (REC), 145, 147, 210
- research governance, 80
- Research Institutes/Parks in Trusts, 4
- research meetings
 - activities after meeting, 181–182
 - application for, 179–180
 - benefits, 181
 - choice of, 179
 - funding opportunities, 180
 - introduction, 179
 - networking at, 180–181
 - oral presentations, 181

Index

- research meetings (cont.)
 overview, 185–186
 planning time at, 180
 poster presentations, 181
 preparation for, 179–180
 social media, 181
 sponsorship for, 181
 summary, 182
- research trainee responsibilities, 168
- ResearchGate, 27
- respect ground rule, 154
- respiratory distress syndrome (RDS), 204
- results section of research paper, 194
- Reuters, Thomas, 192
- ring-fencing time, 11
- risk concept in epidemiological research, 119–120
- risk ratio (RR), 115
- Royal College of General Practitioners, 22
- Royal College of Obstetrics & Gynaecology (RCOG), 201, 202, 205, 209–210, 228, 229, 242
- sacro-coccygeal teratoma (SCT), 216
- sample size calculations, 77–78
- science, technology, engineer and medicine (STEM) careers, 24
- scientific research availability on social media, 24
- Scottish Intercollegiate Guidelines Network (SIGN), 57
- Screening for Pregnancy Endpoints (SCOPE) study, 102
- secondary analysis, 206
- secondary research, 231
- selection bias, 241
- Serum, Urine and Ultrasound Screening Study (SURUSS), 211
- Service User Research Enterprise (SURE), 153
- Shift.ms tool, 25
- Shipman, Harold, 1
- short-form health survey (SF-36), 77
- short tandem repeats (STR), 88
- sibling relative risk, 89
- Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction trial, 216
- simple randomisation, 78
- single nucleotide polymorphisms (SNPs), 88, 89, 93, 220
- Soapbox Science, 24
- social media, 181. *See also* computer skills for social media
- Social Media Highway Code, 22
- socio-demographic profiles, 66
- Solomon technique, 216
- somatic mutations, 89
- space-time clustering, 139
- spatial correlation, 139
- spatio-temporal image correlation (STIC), 213
- Special Interest Group in Reproductive Endocrinology, 243
- specialist medical training
 Academic Clinical Fellowship, 1–2
 Academic Clinical Lectureships, 2
 academic trainee research, 1
 career progression after, 3
 clinical trainee research, 3–4
 conclusion, 6
 content of research, 6
 introduction, 1, 2f
 Out of Programme (OOP) academic trainee, 2
 research aims, 4–6
 types of research, 6
- specificity, defined, 123
- spelling/grammar checks, 15
- sponsorship for research meetings, 181
- spreadsheet software, 16, 17
- ST segment analysis (STAN), 214
- staff employment, 107–108
- standard deviation (SD), 112
- standard error statistics, 113
- Standardised Mortality Ratio, 125
- statistical cure, 137
- statistical modelling in epidemiological research, 127–129, 128f
- statistical software, 16–17, 17f
- statistics in medical research
 association between continuous variables, 116f, 116f–117
 bias in, 113
 central tendency and variation, 112
 clustered data, 114
 comparing more than two means, 115
 comparing more than two proportions, 115–116
 comparing two means, 114
 comparing two proportions, 115t, 115
 concepts involved with, 113–114
 confidence intervals, 113
 confounding, 117t
 exploring/checking data, 112
 hypothesis testing, 113
 introduction, 110
 meta-analysis, 117
 methods of analysis, 114–117
 necessity of, 110
 parametric/non-parametric statistics, 113–114
 planning and performance of, 110–111
 power, 113–114
 risks and odds, 112
- software for, 117–118
- standard error, 113
- summarising data, 111–112
- types of data, 111f, 111f–112
- uses for, 110
- stem cell therapy, 208
- STOPPIT trial, 72
- stratification in epidemiological research, 127
- stratified randomisation, 78
- strength of association, 123
- structural measures in audits, 54
- studentships, 178
- study design in funding medical research, 173–174
- sudden infant death syndrome (SIDS) research, 50
- supervised medical research
 background, 165
 choosing candidate, 166
 choosing supervisor, 165–166
 choosing the right project, 167
 conclusions, 170
 frequency and type, 169
 future plans, 168
 managing disagreements, 169–170
 networking and support, 168
 during project, 167–168
 research trainee responsibilities, 168
 starting a research project, 167
 starting supervision process, 166–167
 supervisor responsibilities, 168
 supervisor/trainee expectations, 168–169
- supervisor responsibilities in research, 168
- surrogate outcomes, 138
- systematic literature reviews, 40t, 40, 198, 203–204, 242
- systems biology. *See* -omic research
- tablet devices, 13, 15
- tabloid papers, 39
- Taiwanese National Health Insurance Database, 238
- tasking with medical research, 9f, 9
- taxpayer funding sources, 177
- Term Breech Trial, 72, 204–205
- test performance in epidemiological research, 132
- theoretical epidemiology, 119
- therapeutic misconception, 146
- time constraint concerns, 21, 22f
- time management in medical research
 conclusion, 11
 deadlines, 10
 delegation, 10–11
 emails, 11
 hiding, 11

- introduction, 8
- planning for, 8
- prioritisation in, 9f
- resources utilization, 11
- saving time, 10
- setting goals, 8–9
- tasking with, 9f, 9
- timetabling in, 9
- wasting time, 10
- time sequence, 123
- time series, 139–140
- timetabling in medical research, 9
- tissue-based research, 245–246
- Tracheal Occlusion To Accelerate Lung Growth Trial (TOTAL), 215
- trainee advice in laboratory research, 221–222
- transcriptomics, 98
- translational research, 256
- transplacental drug therapy, 208
- travel and exchange grant, 176
- Trial of Randomised Umbilical and Fetal Flow in Europe (TRUFFLE), 211
- TRIP database, 32, 33
- trophoblast laboratory research, 218
- Twin anaemia polycythaemia sequence (TAPS), 213
- twin reversed arterial perfusion sequence (TRAP), 216
- twin-to-twin-transfusion syndrome (TTTS), 213, 215, 216
- Twitter, 26
- two-arm parallel group, 73
- UK Obstetric Surveillance System (UKOSS), 212
- ulipristal acetate (UPA), 248–249
- ultrasound observations, 212, 213
- understanding animal research, 87
- United Kingdom Ethics Committee Authority (UKECA), 210
- United Kingdom Obstetric Surveillance System (UKOSS), 229
- Universities Federation for Animal Welfare (UFAW), 83
- university guidelines for medical thesis, 198
- unknown data, 107
- User Involvement in Voluntary Organisations Shared Learning Group, 155–156
- vaginal prolapse case example, 69
- valid consent, 142–143
- validation, 136f, 136f–138, 137f, 138f
- validity in epidemiological research, 131t–133, 132f, 132t
- variable numbers of tandem repeats (VNTR), 88, 89
- variables
 - association between continuous variables, 116f, 116f–117
 - binary variables, 111
 - categorical variables, 111
 - continuous variables, 111, 116f, 116f–117
 - discrete variables, 111
 - individual patient survival, 134
- video in medical research
 - presentations, 184–185
- visual aids in medical research papers, 183–185
- voice recognition software, 18
- voluntariness, 142–143, 148
- vulval cancer, 258
- Walport Fellowship, 1
- Web 2.0 technology, 20, 21f
- Web of Science, 192
- Wellcome Trust, 190, 193, 237
- whole genome sequencing (WGS) technologies, 94
- withdrawal in epidemiological research, 135–136
- word processing, 15f, 15
- World Endometriosis Research Foundation (WERF), 246
- World Health Organization (WHO), 231, 239
- World Medical Association, 189
- writing for publication
 - audits, 193
 - case reports, 193–194
 - choosing journals, 193
 - conclusion, 195
 - Equator network, 188
 - esteem measures, 193
 - ethics approval, 189
 - impact factor, 192
 - introduction, 188
 - medical thesis, 199
 - medicinal products and RCTs, 190
 - open access, 192–193
 - original data, 194
 - plagiarism concerns, 195
 - prospective registration, 189–190
 - reporting guidelines, 191–192
 - research vs. audit, 190–191
 - before submission, 194–195
 - types of research studies, 188–189, 189t